Literature DB >> 21727133

Induced pluripotent stem cells for modelling human diseases.

Juli J Unternaehrer1, George Q Daley.   

Abstract

Research into the pathophysiological mechanisms of human disease and the development of targeted therapies have been hindered by a lack of predictive disease models that can be experimentally manipulated in vitro. This review describes the current state of modelling human diseases with the use of human induced pluripotent stem (iPS) cell lines. To date, a variety of neurodegenerative diseases, haematopoietic disorders, metabolic conditions and cardiovascular pathologies have been captured in a Petri dish through reprogramming of patient cells into iPS cells followed by directed differentiation of disease-relevant cells and tissues. However, realizing the true promise of iPS cells for advancing our basic understanding of disease and ultimately providing novel cell-based therapies will require more refined protocols for generating the highly specialized cells affected by disease, coupled with strategies for drug discovery and cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21727133      PMCID: PMC3130418          DOI: 10.1098/rstb.2011.0017

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  45 in total

Review 1.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.

Authors:  Daniel J Rader; Jonathan Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

2.  Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome).

Authors:  Jakub Tolar; In-Hyun Park; Lily Xia; Chris J Lees; Brandon Peacock; Beau Webber; Ron T McElmurry; Cindy R Eide; Paul J Orchard; Michael Kyba; Mark J Osborn; Troy C Lund; John E Wagner; George Q Daley; Bruce R Blazar
Journal:  Blood       Date:  2010-10-29       Impact factor: 22.113

3.  Marked differences in differentiation propensity among human embryonic stem cell lines.

Authors:  Kenji Osafune; Leslie Caron; Malgorzata Borowiak; Rita J Martinez; Claire S Fitz-Gerald; Yasunori Sato; Chad A Cowan; Kenneth R Chien; Douglas A Melton
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

4.  Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts.

Authors:  Prashant Mali; Zhaohui Ye; Holly H Hommond; Xiaobing Yu; Jeff Lin; Guibin Chen; Jizhong Zou; Linzhao Cheng
Journal:  Stem Cells       Date:  2008-05-29       Impact factor: 6.277

Review 5.  The molecular basis of type 1 glycogen storage diseases.

Authors:  J Y Chou
Journal:  Curr Mol Med       Date:  2001-03       Impact factor: 2.222

6.  Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons.

Authors:  John T Dimos; Kit T Rodolfa; Kathy K Niakan; Laurin M Weisenthal; Hiroshi Mitsumoto; Wendy Chung; Gist F Croft; Genevieve Saphier; Rudy Leibel; Robin Goland; Hynek Wichterle; Christopher E Henderson; Kevin Eggan
Journal:  Science       Date:  2008-07-31       Impact factor: 47.728

Review 7.  Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development.

Authors:  Charles E Murry; Gordon Keller
Journal:  Cell       Date:  2008-02-22       Impact factor: 41.582

Review 8.  Alpha-1-antitrypsin deficiency: diagnosis and treatment.

Authors:  David H Perlmutter
Journal:  Clin Liver Dis       Date:  2004-11       Impact factor: 6.126

9.  Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome.

Authors:  Michael Brunner; Xuwen Peng; Gong Xin Liu; Xiao-Qin Ren; Ohad Ziv; Bum-Rak Choi; Rajesh Mathur; Mohammed Hajjiri; Katja E Odening; Eric Steinberg; Eduardo J Folco; Ekatherini Pringa; Jason Centracchio; Roland R Macharzina; Tammy Donahay; Lorraine Schofield; Naveed Rana; Malcolm Kirk; Gary F Mitchell; Athena Poppas; Manfred Zehender; Gideon Koren
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

10.  Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease.

Authors:  Marius Wernig; Jian-Ping Zhao; Jan Pruszak; Eva Hedlund; Dongdong Fu; Frank Soldner; Vania Broccoli; Martha Constantine-Paton; Ole Isacson; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

View more
  38 in total

Review 1.  Phenotyping patient-derived cells for translational studies in cardiovascular disease.

Authors:  Stanley Y Shaw; Ari D Brettman
Journal:  Circulation       Date:  2011-11-29       Impact factor: 29.690

Review 2.  Cellular reprogramming: a new technology frontier in pharmaceutical research.

Authors:  Amy Brock; Hui-Tong Goh; Binxia Yang; Yu Lu; Hu Li; Yuin-Han Loh
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

Review 3.  Stem cell sources for vascular tissue engineering and regeneration.

Authors:  Vivek K Bajpai; Stelios T Andreadis
Journal:  Tissue Eng Part B Rev       Date:  2012-07-03       Impact factor: 6.389

Review 4.  The pharmacology of regenerative medicine.

Authors:  George J Christ; Justin M Saul; Mark E Furth; Karl-Erik Andersson
Journal:  Pharmacol Rev       Date:  2013-07-01       Impact factor: 25.468

Review 5.  The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease.

Authors:  Lena F Burbulla; Dimitri Krainc
Journal:  Neurobiol Dis       Date:  2019-07-25       Impact factor: 5.996

6.  The evolving biology of cell reprogramming.

Authors:  Ian Wilmut; Gareth Sullivan; Ian Chambers
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-08-12       Impact factor: 6.237

7.  Microfluidic bioreactor for dynamic regulation of early mesodermal commitment in human pluripotent stem cells.

Authors:  Elisa Cimetta; Dario Sirabella; Keith Yeager; Kathryn Davidson; Joseph Simon; Randall T Moon; Gordana Vunjak-Novakovic
Journal:  Lab Chip       Date:  2013-02-07       Impact factor: 6.799

Review 8.  Bioreactor engineering of stem cell environments.

Authors:  Nina Tandon; Darja Marolt; Elisa Cimetta; Gordana Vunjak-Novakovic
Journal:  Biotechnol Adv       Date:  2013-03-24       Impact factor: 14.227

Review 9.  Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration.

Authors:  Daniel J Cooper; Giulia Zunino; John L Bixby; Vance P Lemmon
Journal:  Mol Cell Neurosci       Date:  2016-07-18       Impact factor: 4.314

10.  Therapeutic transdifferentiation: a novel approach for vascular disease.

Authors:  John P Cooke
Journal:  Circ Res       Date:  2013-03-01       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.